Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 168

1.

Amelioration of muscular dystrophy by transgenic expression of Niemann-Pick C1.

Steen MS, Adams ME, Tesch Y, Froehner SC.

Mol Biol Cell. 2009 Jan;20(1):146-52. doi: 10.1091/mbc.E08-08-0811. Epub 2008 Oct 22.

2.

Enhanced expression of the alpha 7 beta 1 integrin reduces muscular dystrophy and restores viability in dystrophic mice.

Burkin DJ, Wallace GQ, Nicol KJ, Kaufman DJ, Kaufman SJ.

J Cell Biol. 2001 Mar 19;152(6):1207-18.

3.

Mdx mice inducibly expressing dystrophin provide insights into the potential of gene therapy for duchenne muscular dystrophy.

Ahmad A, Brinson M, Hodges BL, Chamberlain JS, Amalfitano A.

Hum Mol Genet. 2000 Oct 12;9(17):2507-15.

PMID:
11030755
4.

Temporal gene expression profiling of dystrophin-deficient (mdx) mouse diaphragm identifies conserved and muscle group-specific mechanisms in the pathogenesis of muscular dystrophy.

Porter JD, Merriam AP, Leahy P, Gong B, Feuerman J, Cheng G, Khanna S.

Hum Mol Genet. 2004 Feb 1;13(3):257-69. Epub 2003 Dec 17.

PMID:
14681298
5.

IGF-II ameliorates the dystrophic phenotype and coordinately down-regulates programmed cell death.

Smith J, Goldsmith C, Ward A, LeDieu R.

Cell Death Differ. 2000 Nov;7(11):1109-18.

6.

Delivery of AAV2/9-microdystrophin genes incorporating helix 1 of the coiled-coil motif in the C-terminal domain of dystrophin improves muscle pathology and restores the level of α1-syntrophin and α-dystrobrevin in skeletal muscles of mdx mice.

Koo T, Malerba A, Athanasopoulos T, Trollet C, Boldrin L, Ferry A, Popplewell L, Foster H, Foster K, Dickson G.

Hum Gene Ther. 2011 Nov;22(11):1379-88. doi: 10.1089/hum.2011.020. Epub 2011 May 25.

7.
8.

A nitric oxide synthase transgene ameliorates muscular dystrophy in mdx mice.

Wehling M, Spencer MJ, Tidball JG.

J Cell Biol. 2001 Oct 1;155(1):123-31.

9.

The mouse dystrophin muscle promoter/enhancer drives expression of mini-dystrophin in transgenic mdx mice and rescues the dystrophy in these mice.

Anderson CL, De Repentigny Y, Cifelli C, Marshall P, Renaud JM, Worton RG, Kothary R.

Mol Ther. 2006 Nov;14(5):724-34. Epub 2006 Jun 27.

11.

Therapeutic potential of PEGylated insulin-like growth factor I for skeletal muscle disease evaluated in two murine models of muscular dystrophy.

Gehrig SM, van der Poel C, Hoeflich A, Naim T, Lynch GS, Metzger F.

Growth Horm IGF Res. 2012 Apr;22(2):69-75. doi: 10.1016/j.ghir.2012.02.004. Epub 2012 Mar 15.

PMID:
22424862
12.

Analysis of gene expression differences between utrophin/dystrophin-deficient vs mdx skeletal muscles reveals a specific upregulation of slow muscle genes in limb muscles.

Baker PE, Kearney JA, Gong B, Merriam AP, Kuhn DE, Porter JD, Rafael-Fortney JA.

Neurogenetics. 2006 May;7(2):81-91. Epub 2006 Mar 9.

PMID:
16525850
13.

Transgenic overexpression of caveolin-3 in skeletal muscle fibers induces a Duchenne-like muscular dystrophy phenotype.

Galbiati F, Volonte D, Chu JB, Li M, Fine SW, Fu M, Bermudez J, Pedemonte M, Weidenheim KM, Pestell RG, Minetti C, Lisanti MP.

Proc Natl Acad Sci U S A. 2000 Aug 15;97(17):9689-94.

14.
15.

Modular flexibility of dystrophin: implications for gene therapy of Duchenne muscular dystrophy.

Harper SQ, Hauser MA, DelloRusso C, Duan D, Crawford RW, Phelps SF, Harper HA, Robinson AS, Engelhardt JF, Brooks SV, Chamberlain JS.

Nat Med. 2002 Mar;8(3):253-61.

PMID:
11875496
16.

Localized treatment with a novel FDA-approved proteasome inhibitor blocks the degradation of dystrophin and dystrophin-associated proteins in mdx mice.

Bonuccelli G, Sotgia F, Capozza F, Gazzerro E, Minetti C, Lisanti MP.

Cell Cycle. 2007 May 15;6(10):1242-8. Epub 2007 May 27.

PMID:
17495527
17.

Differential targeting of nNOS and AQP4 to dystrophin-deficient sarcolemma by membrane-directed alpha-dystrobrevin.

Adams ME, Tesch Y, Percival JM, Albrecht DE, Conhaim JI, Anderson K, Froehner SC.

J Cell Sci. 2008 Jan 1;121(Pt 1):48-54. Epub 2007 Dec 4.

18.

Hsp72 preserves muscle function and slows progression of severe muscular dystrophy.

Gehrig SM, van der Poel C, Sayer TA, Schertzer JD, Henstridge DC, Church JE, Lamon S, Russell AP, Davies KE, Febbraio MA, Lynch GS.

Nature. 2012 Apr 4;484(7394):394-8. doi: 10.1038/nature10980.

PMID:
22495301
19.

A highly functional mini-dystrophin/GFP fusion gene for cell and gene therapy studies of Duchenne muscular dystrophy.

Li S, Kimura E, Ng R, Fall BM, Meuse L, Reyes M, Faulkner JA, Chamberlain JS.

Hum Mol Genet. 2006 May 15;15(10):1610-22. Epub 2006 Apr 4.

PMID:
16595609
20.

Overexpression of the cytotoxic T cell GalNAc transferase in skeletal muscle inhibits muscular dystrophy in mdx mice.

Nguyen HH, Jayasinha V, Xia B, Hoyte K, Martin PT.

Proc Natl Acad Sci U S A. 2002 Apr 16;99(8):5616-21.

Supplemental Content

Support Center